INSL3 and RXFP2: a binding, cAMP, and trafficking assay guide

1) Qualify the ligand as a folded disulfide system

INSL3 belongs to the insulin/relaxin superfamily and is commonly represented as an A chain and a B chain connected by two interchain disulfides, with a third disulfide within the A chain. This topology is not decorative. Chemical synthesis of rat INSL3 required separate preparation of the constituent chains followed by combination and chemical-integrity testing before biological experiments.^[1] Later structure–activity studies showed that analogs can retain receptor binding while losing signaling when the native framework is altered.^[2,3]

Record species, exact A- and B-chain sequences, processing state, terminal groups, counterion, peptide-content basis, lot, and storage history. Confirm intact mass, but do not treat correct mass alone as proof of correct disulfide connectivity. Use a mapping method capable of distinguishing disulfide isomers, alongside a stability-indicating chromatographic assay. Reduced chains, scrambled isomers, partially oxidized material, aggregates, and residual synthetic intermediates can all share part of the expected analytical profile while producing different receptor responses.

Native processing can also vary across species. Mass-spectrometric analysis of purified boar INSL3 identified a biologically active monomeric B-C-A protein with three site-specific disulfides, rather than only the simplified two-chain form often used as a reagent.^[4] The experimental label must therefore state whether the material is a mature two-chain synthetic peptide, a single-chain precursor-like protein, or an analog. Results from these forms should not be pooled without demonstrating equivalent RXFP2 pharmacology.

2) Separate high-affinity binding from receptor activation

RXFP2 is a leucine-rich-repeat-containing class A GPCR. The receptor’s large extracellular region provides a major high-affinity interaction surface, while activation requires additional communication with the transmembrane domain. INSL3 structure–activity work supports a two-stage model: important B-chain residues anchor the ligand, while the A-chain region and constrained three-dimensional arrangement help trigger signaling.^[2,3]

This distinction creates an unusually strong assay control. In one study, replacing the A11-B10 disulfide with an amide linkage left receptor binding largely intact but abolished cAMP production.^[2] In another, removing or substituting the intra-A-chain disulfide retained nearly full RXFP2 binding but eliminated cAMP activity; dicarba replacements that preserved geometry restored activity.^[3] These are direct demonstrations that occupancy and agonism are different measurements.

Run competition binding and functional response in parallel using the same qualified peptide lot. For binding, document receptor expression, tracer concentration, nonspecific binding, incubation time, temperature, and the fitted competition model. Include parental or empty-vector membranes and an excess of unlabeled reference ligand. A displacement curve establishes competition at the receptor preparation; it does not prove that the test material is an agonist.

3) Build a quantitative cAMP experiment

RXFP2 activation is commonly measured through Gαs-dependent accumulation of cAMP. Use a direct cAMP assay or a validated real-time biosensor, and establish the dynamic range with a pathway-level positive control. Generate full concentration-response curves for native INSL3 and a reference agonist. Report potency, maximum response, slope, baseline, assay window, number of independent experiments, and the model used for fitting rather than only a percent-of-control value.

Receptor reserve can make a partial or damaged ligand look fully active in a highly overexpressing line. Create an RXFP2 expression series or compare clones with quantified surface abundance. Plot both potency and efficacy against receptor density. A low-expression system may better expose reduced coupling efficiency, while a high-expression system can be useful for sensitive screening. Neither alone defines intrinsic efficacy.

Preserve kinetics. RXFP2 signaling has been reported to remain elevated for hours in transfected HEK293T cells.^[5] Measure an early time course to capture onset and a longer time course to detect persistence. Include washout arms and a membrane-impermeant ligand-removal strategy where validated. Endpoint accumulation can combine initial activation, phosphodiesterase activity, receptor persistence, and assay saturation; time-resolved measurements help separate these processes.

Control peptide exposure in the complete matrix. Incubate the reagent in buffer, conditioned medium, and cell-containing wells at the experimental temperature, then quantify intact material across the assay interval by LC–MS or another validated method. Use time-zero, no-cell, low-binding-vessel, and vehicle controls. Serum proteins may reduce surface loss but also change free ligand. Nominal well concentration should not be presented as receptor exposure without recovery data.

4) Resolve RXFP2 dependence and family cross-reactivity

The minimum recombinant panel includes matched RXFP2, RXFP1, and empty-vector cells in one parental background. Quantify surface expression rather than assuming equal receptor abundance from equal plasmid input. Test INSL3 alongside relaxin-2 or another validated RXFP1 comparator. Species orthologs must be treated as distinct reagents because changes in ligand and receptor sequence can shift potency and efficacy.

Demonstrate causality genetically in a responsive native or engineered system. Disrupt RXFP2, confirm loss of receptor transcript and surface protein, and restore the response with expression-matched rescue. An unrelated Gαs-coupled receptor should remain functional after editing. Pharmacological inhibition can support the result, but inhibitor selectivity must be established in the exact receptor panel rather than imported from another assay.

Beware of endogenous receptor background. HEK-derived lines can vary by passage, subclone, and culture conditions, and downstream cAMP machinery can drift. Retain parental-cell responses in every experiment. If a phenotype appears only after prolonged ligand exposure, verify that it is lost with RXFP2 disruption and is not reproduced by an equivalent cAMP stimulus. That design separates receptor-specific biology from a generic consequence of raising cAMP.

5) Test trafficking instead of assuming a conventional GPCR pattern

Many GPCRs undergo rapid agonist-dependent phosphorylation, beta-arrestin recruitment, and internalization. RXFP2 may behave differently. Callander and colleagues observed prolonged cAMP signaling, weak agonist-dependent phosphorylation, little beta-arrestin recruitment, and poor internalization of RXFP2 after INSL3 stimulation in HEK293T cells; the angiotensin AT1 receptor provided a rapidly internalizing comparator.^[5] This is a useful hypothesis, not permission to omit trafficking measurements in a new system.

Measure surface RXFP2 at baseline and multiple post-stimulation times using an extracellular tag, antibody, or validated ligand-binding approach. Pair that measurement with beta-arrestin recruitment and cAMP in the same cellular background. Include a known internalizing receptor to prove that the imaging or complementation assay can detect redistribution. Fluorescent receptor tags require a functionality check because placement and expression can alter trafficking.

Distinguish persistent receptor signaling from persistent ligand. After a defined pulse, remove extracellular INSL3, verify removal analytically, and follow cAMP decay. Compare continuous exposure, washout, and receptor-block conditions. If cAMP persists only while intact peptide remains in the medium, slow ligand loss is a simpler explanation than an unusually stable active receptor state.

6) A reproducible INSL3–RXFP2 workflow

1. Define the molecular form. Document chains, species, processing state, termini, counterion, and content basis.
2. Verify chemical integrity. Combine intact mass, disulfide mapping, chromatography, and matrix recovery.
3. Calibrate the receptor panel. Quantify RXFP2 and RXFP1 surface abundance in a common background.
4. Measure occupancy and efficacy separately. Pair binding with full cAMP concentration-response curves.
5. Challenge the mechanism. Use structure–activity controls that uncouple binding from activation.
6. Prove receptor dependence. Combine parental cells, knockout, expression-matched rescue, and pathway controls.
7. Resolve time. Test ligand persistence, receptor trafficking, beta-arrestin recruitment, and signal decay after washout.

The interpretable experimental unit is a chemically and conformationally qualified INSL3 form tested in expression-matched RXFP2 and RXFP1 systems, with binding, cAMP kinetics, genetic rescue, trafficking, and peptide-recovery data. This design separates true RXFP2 agonism from disulfide scrambling, receptor reserve, family cross-reactivity, nominal-concentration error, and prolonged exposure.